BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Two Intranasal Candidates Get Closer to Augmenting Pandemic Response

  Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.

  September 22, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Business

  Spark Founders Launch Opus Genetics to Tackle Rare Forms of Blindness

  The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.

  September 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  New Atopic Dermatitis Option Available as FDA Approves Incyte’s Opzelura

  FDA approved Incyte’s Opzelura (ruxolitinib) cream for atopic dermatitis (AD) for the short-term and non-continuous chronic treatment of mild to moderate AD.

  September 22, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  A Prophylactic for Poison Ivy? Phase I Trial Set to Begin

  The Phase I randomized, double-blind, placebo-controlled, single ascending dose study will assess the tolerability and safety of the compound PDC-APB when delivered via intramuscular injection.

  September 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  National Survey: “Trust” at the Heart of Low U.S. Vaccination Rates

  The survey of 20,699 Americans found that the unvaccinated – 35% of respondents – didn’t trust that the vaccines were safe or effective.

  September 22, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Can Clover’s Vaccine Candidate Stand Its Ground Against COVID Variants?

  On Wednesday, the company said that its adjuvanted protein-based COVID-19 vaccine candidate, dubbed SCB-2019 (CpG 1018/Alum), hit the primary and secondary efficacy endpoints in a Phase II/III clinical trial.

  September 22, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  Business

  Biogen Shares Dip at Slow Aduhelm Uptake and Cost-Cutting Rumors

  As of September 11, slightly over 100 Alzheimer’s patients had received the drug, reported to be dramatically below Biogen’s internal projections and Wall Street expectations.

  September 22, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Llama Nanobodies May be Missing Link in COVID-19 Therapeutics

  Monoclonal antibodies play a key role in the treatment of COVID-19, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies.

  September 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Global Roundup: Monument Therapeutics Takes New Approach to Treat Schizophrenia

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  September 22, 2021

   · 

  7 min read

   · 

  Alex Keown
• 

  Business

  Aurion Biotech CEO: “How You React Now Determines Your Next Success”

  Aurion Biotech is focused on curative and restorative treatments for corneal endothelial disease.

  September 22, 2021

   · 

  4 min read

   · 

  Gail Dutton